https://technical.ly/baltimore/wp-content/themes/national Camden Partners Nexus co-leads $3.7M investment in pharmaceutical company treating hearing loss - Technical.ly Baltimore

Business

Dec. 12, 2018 2:12 pm

Camden Partners Nexus co-leads $3.7M investment in pharmaceutical company treating hearing loss

The funding from the Baltimore-based venture fund and Savoir Capital is part of a Series A round for Spiral Therapeutics, which has an R&D presence at Johns Hopkins.

Lab space at Johns Hopkins' FastForward 1812.

(Photo by Stephen Babcock)

Early-stage pharmaceutical company Spiral Therapeutics received $3.7 million in new investment as it looks to advance treatments for hearing loss and other inner ear disorders.

The first close of the Series A round was led by Baltimore-based Camden Partners Nexus and Savoir Capital.

The company’s initial drug candidate, LPT99, moved into the clinical phase of a Phase I study this month. In the fall, the company reported positive feedback from the U.S. Food and Drug Administration in response to an initial submission, which plans to develop the treatment for the prevention of chemotherapy-induced hearing loss in pediatric patients. The company is also exploring further use for other types of hearing loss.

“This round of financing allows us to take LPT99 into the clinic and further validates our development strategy,” said Hugo Peris, founder and CEO of Spiral Therapeutics.

Launched in early 2016, the San Francisco–based company has a research and development presence in Baltimore through a collaboration with Johns Hopkins, as well as in Barcelona, Spain.

“Spiral Therapeutics brings together innovative therapies addressing inner ear disorders and a seasoned and energetic management team,” George Petrocheilos, a general partner at Camden Partners who will join the company’s board, said in a statement. “Its solid R&D foundation and the meaningful collaborations with leading medical institutions like Johns Hopkins and UCSF make Spiral an ideal investment for Camden.”

Camden Partners Nexus, the biomedical-focused venture fund of Inner Harbor–based Camden Partners that focuses on companies commercializing research, recently made investments in local startups including Sisu Global Health and WindMIL Therapeutics, among other deals since making its final close at the end of 2017.

Advertisement

Organizations: Camden Partners
-30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here

Advertisement

Sickweather aims to help HR managers get ahead of what’s going around

4 university entrepreneurs talk about the passion behind the products

Maryland E-Nnovation initiative provides matching funds for tech-focused research endowments

SPONSORED

Baltimore

Why a modern office matters for Asymmetrik’s growing culture

Baltimore, MD 21201

14 West

Business Analyst

Apply Now
Baltimore, MD 21201

14 West

Solutions Specialist

Apply Now
Baltimore, MD

SmartLogic

Developer

Apply Now

Maryland companies raised more than $1B in venture funding in 2018

Maryland cybersecurity company Syncurity closes $2M seed round

Here’s a look at the impact-minded startups that just finished Conscious Venture Lab

SPONSORED

Baltimore

SmartLogic propels digital transformation aboard Baltimore Water Taxi

Baltimore, MD 21201

Agora Financial, an Agora Company

Front End Web Developer

Apply Now
Baltimore, MD 21201

Agora Financial

Email Deliverability Specialist

Apply Now
Annapolis Junction, MD

Asymmetrik

FULL-STACK DEVELOPER

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!